We suggest, that partial agonists of α2A/B-adrenoreceptors with a very weak intrinsic activity seem to offer a potential for a good and effective treatment of obesity, with a lower risk of side effects associated with the cardiovascular system. This evidence concerns the gene IGKV2D-29 and Obesity.